The 2nd Regional Energy Transition Outlook for Africa Advisory Meeting will focus on a discussion of the preliminary analysis.
Vous n'êtes pas connecté
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 1,400% and 273.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The 2nd Regional Energy Transition Outlook for Africa Advisory Meeting will focus on a discussion of the preliminary analysis.